Catheter Precision reports vote results; 641,616 shares voted

Q: How many shares were outstanding for VTAK on the record date?

There were 1,487,266 shares outstanding as of September 10, 2025.

Q: What was the quorum at the Special Meeting for VTAK?

641,616 shares were represented, approximately 43.1% of shares entitled to vote.

Q: How many proposals were considered at VTAK’s meeting?

Stockholders considered three proposals.

Q: What were the vote results for Proposal 1 (VTAK)?

497,162 for, 133,882 against, 10,571 abstentions.

Q: What were the vote results for Proposal 2 (VTAK)?

610,134 for, 16,778 against, 14,703 abstentions.

Q: What were the vote results for Proposal 3 (VTAK)?

514,362 for, 120,394 against, 6,860 abstentions.

Catheter Precision (VTAK) reported the results of a stockholder Special Meeting held on October 10, 2025.

Accepted by SEC EDGAR 10/15/2025 - 04:15 PM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Catheter Precision (VTAK) reported the results of a stockholder Special Meeting held on October 10, 2025. Of the 1,487,266 shares outstanding as of September 10, 2025 (the record date), 641,616 shares were represented in person or by proxy, constituting approximately 43.1% of shares entitled to vote.

Stockholders considered three proposals. Reported vote totals were: Proposal 1 — 497,162 for, 133,882 against, 10,571 abstentions; Proposal 2 — 610,134 for, 16,778 against, 14,703 abstentions; Proposal 3 — 514,362 for, 120,394 against, 6,860 abstentions.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Catheter Precision (VTAK) disclose in this 8-K?

It reported stockholder voting results from a Special Meeting on October 10, 2025.

How many shares were outstanding for VTAK on the record date?

There were 1,487,266 shares outstanding as of September 10, 2025.

What was the quorum at the Special Meeting for VTAK?

641,616 shares were represented, approximately 43.1% of shares entitled to vote.

How many proposals were considered at VTAK’s meeting?

Stockholders considered three proposals.

What were the vote results for Proposal 1 (VTAK)?

497,162 for, 133,882 against, 10,571 abstentions.

What were the vote results for Proposal 2 (VTAK)?

610,134 for, 16,778 against, 14,703 abstentions.

What were the vote results for Proposal 3 (VTAK)?

514,362 for, 120,394 against, 6,860 abstentions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

October 10, 2025

Catheter Precision, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-38677		38-3661826
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1670 Highway 160 West

Suite 205

Fort Mill, SC 29708

(Address of principal executive offices, including zip code)

(973) 691-2000

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	VTAK	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On October 10, 2025, the Company held a Special Meeting of stockholders at which, of the 1,487,266 shares of the Company’s common stock outstanding as of September 10, 2025, the record date for the Annual Meeting, 641,616 shares of common stock were represented, either in person or by proxy, constituting, of the shares entitled to vote, approximately 43.1% of the outstanding shares of common stock.

At the Annual Meeting, the Company’s stockholders considered three proposals, which are described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on September 15, 2025. The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below:

Proposal No. 1: To approve an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of our common stock from sixty (60) million shares to five hundred (500) million shares. Proposal No. 1 was approved, based on the following results of voting:

Votes For		Votes Against	Abstentions	Broker Non-Votes
497,162		133,882	10,571	0

Proposal No. 2: To ratify the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2026. Proposal No. 2 was approved, based on the following results of voting:

Votes For		Votes Against	Abstentions	Broker Non-Votes
610,134		16,778	14,703	0

Proposal No. 3: To approve the adjournment or postponement of the Special Meeting, if necessary, to continue to solicit votes for Proposals Nos 1 and/or 2. Proposal No. 3 was approved, based on the following results of voting:

Votes For		Votes Against	Abstentions	Broker Non-Votes
514,362		120,394	6,860	0

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		CATHETER PRECISION, INC.



Date:	October 15, 2025	By:	/s/ Philip Anderson
			Philip Anderson
			Chief Financial Officer

Source: View Original Filing on SEC EDGAR